Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-B-Lactamase- Producing Escherichia coli
We investigated the impact of the piperacillin-tazobactam MIC in the outcome of 39 bloodstream infections due to extended-
spectrum-B-lactamase-producing Escherichia coli. All 11 patients with urinary tract infections survived, irrespective of the MIC.
For other sources, 30-day mortality was lower for isolates with a MIC of
<2 mg/liter than for isolates with a higher MIC (0% ver-
sus 41.1%; P = 0.02